Platform scalability Pelican Expression Technology offers a robust, validated, cost-effective and scalable platform for recombinant protein production, suitable for complex, large-scale manufacturing. This alignment suggests sales opportunities with biotech firms requiring efficient upscaling and diverse protein outputs.

Out-licensing momentum The technology is currently out-licensed for multiple programs, indicating a proven market interest and potential partnerships or co-development deals. Pursue collaborations with biotech developers seeking turnkey production capabilities and risk-sharing arrangements.

Funding momentum Recent funding events, including a $15M investment from Ligand Pharmaceuticals and merged entity primed for growth, signal an ongoing expansion phase. This presents opportunities to engage with portfolio companies and explore manufacturing partnerships aligned with their growth plans.

Targeted customers Platform versatility covers enzymes, peptides, antibody derivatives, and engineered non-natural proteins, appealing to biopharma firms pursuing complex large-molecule programs. Focus outreach on groups developing vaccines and therapeutics with manufacturing bottlenecks.

Competitive positioning Positioned as one of the most comprehensive broadly available protein production platforms in the industry, with demonstrated global adoption. Leverage this differentiator to address prospects seeking scalable, cost-reducing production solutions and faster development timelines.